Breast Cancer Clinical Trial
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
Locally advanced or metastatic disease; locally advanced disease must not be amenable to resection with curative intent.
Phase 1: Subjects with advanced or metastatic solid tumors.
Phase 1: Subjects who have disease progression after treatment with available therapies.
Phase 2: Subjects with advanced or metastatic cervical cancer, gastric cancer (including stomach, esophageal, and GEJ), SCCHN, PD-1 refractory SCCHN and PD-1/PD-L1 relapsed melanoma.
Presence of measurable disease based on RECIST v1.1.
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
Laboratory and medical history parameters not within the Protocol-defined range
Prior treatment with any tumor necrosis factor super family agonist.
Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.
Has not recovered to ≤ Grade 1 from toxic effects of prior therapy.
Active autoimmune disease.
Known active central nervous system metastases and/or carcinomatous meningitis.
Evidence of active, noninfectious pneumonitis or history of interstitial lung disease.
Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.
Known history of human immunodeficiency virus (HIV; HIV 1/2 antibodies).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 33 Locations for this study
Los Angeles California, 90025, United States
Gainesville Florida, 32610, United States
Detroit Michigan, 48201, United States
Saint Louis Missouri, 37201, United States
Hackensack New Jersey, 07601, United States
New York New York, 10065, United States
Chapel Hill North Carolina, 27599, United States
Oklahoma City Oklahoma, 73104, United States
Portland Oregon, 97213, United States
Philadelphia Pennsylvania, 19111, United States
Pittsburgh Pennsylvania, 15232, United States
Nashville Tennessee, 37201, United States
Dallas Texas, 75230, United States
Houston Texas, 77030, United States
Seattle Washington, 98109, United States
Blacktown New South Wales, 2148, Australia
Randwick New South Wales, 2148, Australia
Brisbane Queensland, 4120, Australia
Heidelberg Victoria, 3084, Australia
Perth Western Australia, 6009, Australia
Libramont Chevigny, 6800, Belgium
Antwerpen , 2610, Belgium
Brussels , 1000, Belgium
Brussels , 1200, Belgium
Bruxelles , 1020, Belgium
Charleroi , 6000, Belgium
Ghent , 37201, Belgium
Kortrijk , 8500, Belgium
Barcelona , 08036, Spain
Barcelona , 08036, Spain
Barcelona , 08916, Spain
Barcelona , , Spain
Córdoba , 14004, Spain
Madrid , 28034, Spain
Madrid , 28041, Spain
Madrid , 28050, Spain
Pamplona , 31008, Spain
Sevilla , 41015, Spain
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.